{"title":"欧洲癌症战略管理机构(EASMAC)对治疗、诊断和欧盟政治的可能影响","authors":"C. Melidis","doi":"10.47829/coo.2020.3201","DOIUrl":null,"url":null,"abstract":"Each European Union (EU) country has its own therapeutic and diagnostic protocols for cancer treatment, contrary to the USA. In order to achieve a therapeutic and follow-up harmonization, the existence of a central EU agency can be of paramount importance. The aim of the current paper is to present the (still in paper) European Agency for the Strategic Management Against Cancer (EASMAC) and its possible impact on cancer patient treatment and diagnosis and EU politics in general.","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"2022 26","pages":""},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Possible Impact of a European Agency for the Strategic Management Against Cancer (EASMAC) on Treatment, Diagnosis and EU Politics\",\"authors\":\"C. Melidis\",\"doi\":\"10.47829/coo.2020.3201\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Each European Union (EU) country has its own therapeutic and diagnostic protocols for cancer treatment, contrary to the USA. In order to achieve a therapeutic and follow-up harmonization, the existence of a central EU agency can be of paramount importance. The aim of the current paper is to present the (still in paper) European Agency for the Strategic Management Against Cancer (EASMAC) and its possible impact on cancer patient treatment and diagnosis and EU politics in general.\",\"PeriodicalId\":92766,\"journal\":{\"name\":\"Clinics of oncology\",\"volume\":\"2022 26\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinics of oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47829/coo.2020.3201\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics of oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47829/coo.2020.3201","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Possible Impact of a European Agency for the Strategic Management Against Cancer (EASMAC) on Treatment, Diagnosis and EU Politics
Each European Union (EU) country has its own therapeutic and diagnostic protocols for cancer treatment, contrary to the USA. In order to achieve a therapeutic and follow-up harmonization, the existence of a central EU agency can be of paramount importance. The aim of the current paper is to present the (still in paper) European Agency for the Strategic Management Against Cancer (EASMAC) and its possible impact on cancer patient treatment and diagnosis and EU politics in general.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
